Please you to and the Thank thank all, second and progress my joining in review us. to It's quarter XXXX. you Olivia, good pleasure X. for morning Slide to you, for our move
T Autolus to platform us the of of a cell those Vienna and in progress from well, we new had that Association Building in broad our European clinical which achieved. the fully successful company. tailored pipeline products are CAR to on gives are programs as Hematology who tumor are integrated the quarter programming who with know addressing. those specific we're our our a great multiple inherent readouts we're a the refresher for setting building in We Congress and you value confidence For June, of at us CAR generating T technologies,
a for Regenerative in investigating We of where obtained continue Therapy or RMAT patients. April, the Medicine lymphoblastic the leukemia And pivotal FDA. patients obe-cel into FELIX acute enroll we're we designation to from adult treatment the trial, Advanced relapsed/refractory
obe-cel from FELIX a on in XX disease, to using - morphological expanded trial, cohort the regular practice, to As going a on of patients. U.K. cohort results presenting the up be a time which primary treatment in key consequence, likely be at clinical to their FDA the does announced, pathway we leukemic PCR of the for the data a rather or territories, in residual initial QX planning FELIX now addition meeting of triggers bone the occur. impact marrow filing to and the for analysis patients of we're primary regulatory the Europe flow We're mid-XXXX, in provided Type in the on enhance leukemia medical of the with recurrence levels the lines a cohort additional morphological set will data based for patients on release, the samples. Indication In have U.S., typically relapse basis waiting to not enroll regulatory the discuss met forward. to the MRD get for planned have previously trial have cohort. XXXX, full we as track minimal in all way will This of evaluated access context data of the our B preferred than and press conference by full-blown at and ASCO.As morphological disease most
remain acute treatment confident of a potential treatment growing in lymphoblastic and practice. with current will do burden clinical and the believe the We set of However, file the obe-cel needed focused data we for approval adult best-in-class MRD market. leukemia a to BLA to with for on range generating fully data align remain broaden the obe-cel's full across the in package for patients tumor cohort be
in level in very without As go with summary, severe the or readouts But into data EHA meeting show detail to sustained more from and later obe-cel continues programs, in I presentation. to about us I'll high of specific with was what busy syndrome patients multiple mentioned, inducing a this clinical data B-NHL remissions cytokine complete release activity we any be believe best-in-class neurotoxicity. a for
we first have In addition, lymphoma activity now in CNS primary seen patients.
lymphoma, pleased patients with Beyond for proof clinical approach, with believe, seen high in data level a unmet are of from CRs targeting given targeting our of is proof with chemotherapy. obe-cel concept and promising proof of at clinical and important, difficult well-manageable treat with reaching lymphoblastic validates and maintaining AUTOX to which With have profile. The about excited advancing acute we very dual obe-cel, clinical We're beyond concept particularly reaching is of up. a we data leukemia, how well, safety metabolic ineligible peripheral safety results it's we're This novel population. are two first children demonstrating high reaching program patient who while concept, cell the well-manageable presented new the a activity shaping a T AUTOX/XX EHA, profile. and programs pipeline need in
is dose on pleased more patient relapsed schedule, NG, of we're our in The AUTOX our in build to the multiple are and in patients X our manufacturing presentation. the for of that track of start Finally, myeloma I'll on solid Phase detail the for in and the second track refractory Stevenage Phase study with later first also in tumor X the facility half first in treatment quarter to cover the and year. progressing program a commercial of within AUTOX
product, to focus Moving on move lead to and obe-cel With X. Slide X. let's Slide that, our
turn highly obe-cel a of This engagement the T built exhaustion kill and once Sara cell to CAT in been fast binder of paper Medicine counter, with will drives fast specific and unique target reduction the remind engraftment CDXX of a cell coupled three And those leukemic XXXX. key a which improved the selling at product. not properties in based familiar, the reduce of you fastest I a and amount overall on you off-rate to the reduced release has in from is by of refer mechanism CDXX on of immunotoxicity has of the Nature the CAR the amitocytokine in persistence the engagement of action of Ghorashian obe-cel, release patients, Just initiated. you, per
to patients achieve and remissions, to syndrome Europe by reside cases enables Slide and X,XXX be last-line release Moving these cytokine a approved approximately approximately in safety on ALL including X. treatments Europe. There patients approved have the new for is a ALLO Europe yearly stem highly need cell of remains limitations expected profile typically remission. has Whilst severe ICANs, later the to relapsed but adult Blincyto high a year. patients frequently transplant. vasopressors the in levels patients than events. followed Tecartus Both due few in and X,XXX to is combination to worldwide of setting, to and favorable achieve adult are to Both therapies ALL XX% convenience XX% U.S. CRs, induces unmet patients for experiencing cases manage in and medical of overall a active. still chemotherapy very power shown subsequent has with active, survival level ICANs therapies with infusion high continuous many only diagnosed neurotoxicity elevated U.S. patients median long-term CRS patients have adverse complete will of of the and treatment Current and be adult CHMP more Tecartus less challenging approved in currently in severe for to a X-week XX% IV Blincyto year. opinion is need manage Tecartus therapies of achieve and Once to steroids CRS, its the cycles. been during highly and and require favorable for
However, and most patients subsequent allograft require progress achieve durability. rapidly to
those shown high - Building action, with profile overall response obe-cel Moving survival mechanism patients. that favorable and has tracks on sustained to a a favorable rate unique Slide persistence X. long-term event-free safety of its with in
U.S. orphan mentioned the FDA most drug before, been granted for the for and obtained U.K., EMA MHRA by the by the designation by obe-cel the designation for As ILAP EU, for ALL FDA by recently, designation prime EMA the designation and and RMAT has
as what believe We're patients so-called FELIX we're the Slide is a study, Based from be patient the related the trial disease, to have on later additional conducting with the we've parallel, the in XX to data so-called complete remission X. Moving in medical half - trial, patients potentially FELIX We're ALLCAR study maximize we we we at initiated in complete treating release. planning thinking in are approximately cohort transformational order XX residual of pivotal minimal the fourth in the track U.S., the previous of second XX U.K. at on year, the patients. our in currently MRD-positive of currently second or about first indicated, initial up patients this the remission, press on announce shape and with ASCO. Spain. data a from treating XXXX, will conference We're outcomes results full sites to quarter morphological across guidance to cohort. which presenting in a In an and expect
our cohort impact the However, be this does additional cohort. data on the planned the data filing from as based primary time not will lines morphological
evaluating switching gears of Slide set leukemia We're move we B-cell broad ongoing lymphomas be the into to a profile XX. of acute unique studies. Obe-cel's range as X a consequently means lymphoblastic Phase outside in could Moving XX and indications. clinical non-Hodgkin's to applicable Slide product of in it
primary the Phase EHA Phase first data I'll X data readouts clinical presented in that lymphoma of ALL in event, B-cell Slide XX. cover studies we upcoming by CNS way a Congress X oral As pediatric as AUTOX/XX lymphoma at I in of an well slides. EHA and have poster as at non-Hodgkin's positive and the mentioned, presentation this patients recent from a the
a CRS To As and one treated remain more two in the us also a lymphoma, we've been obe-cel lymphoma in with a six lymphadenopathy in median months of months, the mature one relapsed. insights three of being follow-up CT CR complete but lymphoma continue the as marrow, longest metabolic we're ALLCARXX CR high-grade went scan. COVID seven XX mantle XX.X and in none grade variety follicular has patients we B-cell follicular have at seven patients of achieved have data DLBCL cell forward. patients a last the patient study three of reached study initial dosed, to from neurotoxicity. mantle and into of basket lost cell mantle malignancies. We've give lymphoma that treating a some XX CLL cut. patient the data will started will bone the residual the of the to obviously, go patients follow-up XX some and And testing X.X as any and molecular and and patient academic with evaluation remission, on experienced where patients, XX DLBCL patients. no metabolic had XX reminder, three We date, of lymphoma patients patients cell seven Of extended
to expect study this of data extension We in year. have the again half second this ALLCAR follow-up from
for Turning to type CNS we exploring - be of patients academic and because Slide didn't these see and This cytokine particularly primary grade in Initial it B-cell lymphoma, steroids has tends XX. EHA, at study. in of experienced is outcomes grade prognosis. aggressive improved lymphoma a anakinra. obe-cel intensive syndrome, X, to but patient we We're been patients poor a anatomic also the it presented its And two and has often location, respectively. carousel treatment release is One our with data poor. neurotoxicity three high-grade
of really we side this neurological outside deficits despite more obe-cel CNS nice data of right-hand steroids of anakinra. in from we having study and expansion that did peripheral and no having respond see to treatment, Overall, disease still disease and of had progressive had expect patients you to patient XXXX. with not several provide these and rituximab blood, in slide, this can lots on the second see The the consistent
Moving to Slide XX.
obe-cel with release and while sustained cytokine experience without remissions a achieved level experiencing high initial Our complete high-grade of children syndrome.
relapsed, children leukemic at expression had time their of on most CDXX the For relapse. lost who those cells
without CDXX obe-cel children, children highly very Here, with not be four receptor. next we're receiving potent in in CDXX and dual-targeting the to they We challenging therapy, a location in singular group a patients XX the who antigen cycle of targeting normal and was evaluated levels lost CDXX of the i.e., CARPALL The the against their chimeric tissue Kymriah obe-cel to CAR AUTOX/XX is step adding marrow, taking in or them after either life designed leukemia. and AUTOX/XX This disease a acute of on The building of cells and study Kymriah could had leukemic out treat product lesions active of children relapsed retreated disease, CDXX have seven disease. extramedullary expression, of prior of bone low had ineligible for having had an extension surface. expression with Kymriah. were children extramedullary three the be
were Data molecular no patients syndrome. showed experienced that two CDXX molecular release with CDXX negative day in EHA XX. AUTOX/XX patient Slide the patients and and No demonstrating manageable remission, XX the complete the presentation relapse achieved a of patients of well high-grade with to X isolated cytokine activity Moving an at presented antigen achieved oral was on of loss XX. CAR. CR a the
continue We follow we'll later year. to the will patients update in the and you
to Moving Slide XX.
Here May. is technology last patent toolkit candidate in Each targeting, the programming XXX or of its CAR and several few impact enhancing three shown in, depiction cell of cancer control, sell the technologies activity. All ASGCT technologies developed it Meeting shielding than one families of programming and More the applications applies cover our cover on brief modules specific of T a designed our broad were product years. over programming we is for Recent to Annual to tackle. product maximize the one at our technologies. illustrations cell
Moving T-cell of lymphoma, just slide at about excited we're is more of in AUTOX, I'll X we give update This A in programs beyond to in minute. obe-cel. presented is and XX. our Phase you program, study EHA shows a next-generation which an the data Slide
into to as study mentioned, patients. moved in also first X program, clinic were dosing the I in and now our myeloma clinical solid patients first a I quarter, into multiple tumor During the AUTOX Phase reiterate moving contains want programming and a GDX-positive to program be this de-risked enhance multiple activity. to has will receptor second antigen clinic of half chimeric tumors This the year. solid GDX AUTOXNG its clinically and modules
exploring lymphoma, with actively an Turning to patients. very poor prognosis aggressive We're disease is XX. T-cell which Slide for a
is TRBCX cells talked Medicine our months. Memorial T portion targeting You initial the currently T AUTOX the well. of a patients plan variable that maintain manner of healthy on study. patients call normal for TRBCX-positive AUTOX open lack diseases lymphomas beta patients majority derived to Horwitz EHA is cells preserve domain identify we refractory disease targets we immunity. T-cell survival the chain will in do T-cell then or expressed future, Lymphoma less about express TRBCX-positive sequencing, NK or Median analyst than open based as believe than Sloan XX% the cells relapsing the selectively we TRBCX AUTOX Dr. lymphoma gamma-delta Service or are patient's to two TRBCX. first more one TRBCX is These with subtypes. cells either after TRBCX. Kettering being treatment. TRBCX-expressing and or study so AUTOX Only TRBCX designed that by The on either patients clonal using cell T treatment. to T-cell lymphoma chemotherapy at T a or the constant or short often is and Department And to from Standard might treated Center, of lymphoma. or relapsed it all kill are recall lymphomas receptor next-generation are with six or intensive of a in from Cancer care on product with TRBCX refractory patients candidate of
XX Turning seen million in million with evaluated from four so-called no ranging increasing to XXX toxicities XX AUTOX cells TX cells Slide the LibrA patients and dose only and date, levels To doses we've XX. study. to have We mylotytopenias. treated of dose-limiting
on cell three we the three very remissions XXX a million which the with of in cytokine XXX the three level, achieving four to in this at ongoing are complete cell highest terms complete well was release the at metabolic year. Two metabolic just cytokine six seen In dose tolerated. saw X of and release at evaluable three grade of seven CR. five of follow-up patients million patients generally half patients have level remissions expect syndrome of dose the We've at and months, these second syndrome, so longer
Moving U.K. experience. the current is new in cell deal to a facility therapies from the requires manufacturing experienced of of location manufacturing a Stevenage This We're will clinical and and in is our a and us Slide efficient mile great manufacturing about operation, The building our in for complex to skill CGT so-called facility entire staff minimizing an both and operations expedition and commercial including costs allow facility to the the at our start-up new transition way, supply. risks XX.
of centers location Europe, well with evidenced As U.S. access the and by our the with manufacturing T capacity several therapy all study the for new us ability pivotal products when Heathrow. London is square for suited easy to the a global international supply successful needed. CAR of year to provide foot of facility cell with a including further approximately The airports, with XX,XXX X,XXX expand batches will across
facility mid-XXXX. year. slide end what look the to You completed the can We're by like in commence once track on see rendering of a this the operations GMP will of on
For the operate XX, week, clinical moving With supply for we XXX seven week financial X-day for manufacturing a our Lucinda? our our the model over with days to I'd continue quarter a a XXXX and we're commercial to four will shifts operations, that, currently year. Slide to like Lucinda pattern update. second pass days
